Inventiva SACA

Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results

22 مارس 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D

18 مارس 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D

13 مارس 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed

07 مارس 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3

15 فبراير 2024 16:35:00 بحسب Nasdaq GlobeNewswire

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

24 يناير 2024 16:15:00 بحسب Nasdaq GlobeNewswire

Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank

10 يناير 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program

20 ديسمبر 2023 16:00:00 بحسب Nasdaq GlobeNewswire

Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH

04 ديسمبر 2023 16:05:00 بحسب Nasdaq GlobeNewswire

Inventiva reports 2023 Third Quarter Financial Information¹

21 نوفمبر 2023 16:00:00 بحسب Nasdaq GlobeNewswire

Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023  

06 نوفمبر 2023 16:00:00 بحسب Nasdaq GlobeNewswire

Inventiva reports its 2023 first-half financial results and provides a corporate update

28 سبتمبر 2023 16:00:00 بحسب Nasdaq GlobeNewswire

Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea

20 سبتمبر 2023 16:00:00 بحسب Nasdaq GlobeNewswire

Inventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty certificates

31 أغسطس 2023 01:30:00 بحسب Nasdaq GlobeNewswire

Correction: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update

27 يوليو 2023 16:00:00 بحسب Nasdaq GlobeNewswire

Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association

24 يونيو 2023 02:00:00 بحسب Nasdaq GlobeNewswire

Inventiva announces positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD

13 يونيو 2023 17:00:00 بحسب Nasdaq GlobeNewswire

Inventiva and Echosens launch joint initiative to increase NASH awareness and access to screening for at-risk patients  

08 يونيو 2023 02:30:00 بحسب Nasdaq GlobeNewswire

Inventiva announces five scientific presentations at the EASL International Liver Congress™ 2023

07 يونيو 2023 16:00:00 بحسب Nasdaq GlobeNewswire

Results of the votes of the Combined Shareholders’ General Meeting of May 25, 2023

26 مايو 2023 16:00:00 بحسب Nasdaq GlobeNewswire